#Bioxytran #Scientific #Advisor #Releases #Book #Brain
The book contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen.
BOSTON, MASSACHUSETTS, Oct. 25, 2022 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced that Bioxtran’s Scientific Advisor Prof. Avraham Mayevsky’s book titled Cortical Spreading Depression of Leão: From Mitochondrial Function to Brain Metabolic Score (BMS) (ISBN: 978-3-031-08068-5) was published this month, by the well-known publishing house, Springer. It is available by eBook or Hardcover. The book is directly tied to Bioxytran’s Hypoxia platform technology which uses Oxysense; an analytical method that utilizes the MDX Viewer, which is an FDA approved device to measure tissue oxygenation. Oxysense measures the consumption of oxygen in tissues on a cellular level. Oxysense produces the Brain Metabolic Score (“BMS”), which is a vital part of the approval process for Bioxytran’s acellular oxygen carrier (“AOC”) molecule called BXT-25. Bioxytran has the exclusive license to use the MDX Viewer in clinical research, and plans on using the BMS in its clinical trials for ischemic stroke.
The book is a compilation of 50 years of research by Prof. Mayevsky during which time he published more than 60 scientific articles summarizing the experimental data he discovered. The book expands on the concept of Cortical Spreading Depression (“CSD”) in brain animal models. CSD is a phenomena whereby increased blood flow results in a lower Electroencephalogram (“EEG”), which is a measure of brain activity. Typically, increased blood flow is good, but in 1996, Prof. Mayevsky published his first paper related to his detection of a CSD event for the 1st time in the brain of a neurosurgical patient. Eventually this discovery and others led…